Lexaria Bioscience Revenue vs. Total Debt

LEXX Stock  USD 2.21  0.10  4.74%   
Based on the measurements of profitability obtained from Lexaria Bioscience's financial statements, Lexaria Bioscience Corp may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Lexaria Bioscience's ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2006-11-30
Previous Quarter
84 K
Current Value
84 K
Quarterly Volatility
114.2 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Lexaria Bioscience's Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to rise to 106.04 in 2024, whereas Days Sales Outstanding is likely to drop 26.35 in 2024. At this time, Lexaria Bioscience's Income Tax Expense is fairly stable compared to the past year. Net Interest Income is likely to rise to about 52.2 K in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (23.9 K) in 2024.
For Lexaria Bioscience profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lexaria Bioscience to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lexaria Bioscience Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lexaria Bioscience's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lexaria Bioscience Corp over time as well as its relative position and ranking within its peers.
  

Lexaria Bioscience's Revenue Breakdown by Earning Segment

Check out Correlation Analysis.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexaria Bioscience. If investors know Lexaria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexaria Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.039
Quarterly Revenue Growth
0.081
Return On Assets
(0.38)
Return On Equity
(0.71)
The market value of Lexaria Bioscience Corp is measured differently than its book value, which is the value of Lexaria that is recorded on the company's balance sheet. Investors also form their own opinion of Lexaria Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Lexaria Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexaria Bioscience's market value can be influenced by many factors that don't directly affect Lexaria Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexaria Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexaria Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexaria Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lexaria Bioscience Corp Total Debt vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lexaria Bioscience's current stock value. Our valuation model uses many indicators to compare Lexaria Bioscience value to that of its competitors to determine the firm's financial worth.
Lexaria Bioscience Corp is considered the number one company in revenue category among its peers. It is rated below average in total debt category among its peers making up about  0.30  of Total Debt per Revenue. The ratio of Revenue to Total Debt for Lexaria Bioscience Corp is roughly  3.38 . At this time, Lexaria Bioscience's Total Revenue is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lexaria Bioscience's earnings, one of the primary drivers of an investment's value.

Lexaria Revenue vs. Competition

Lexaria Bioscience Corp is considered the number one company in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 929,556. Lexaria Bioscience totals roughly 464,278 in revenue claiming about 50% of equities under Health Care industry.

Lexaria Total Debt vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Lexaria Bioscience

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
464.28 K
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Lexaria Bioscience

Total Debt

 = 

Bonds

+

Notes

 = 
137.37 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Lexaria Total Debt vs Competition

Lexaria Bioscience Corp is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 134.07 Million. Lexaria Bioscience adds roughly 137,366 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Capitalization  Revenue  Valuation  Workforce

Lexaria Bioscience Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lexaria Bioscience, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lexaria Bioscience will eventually generate negative long term returns. The profitability progress is the general direction of Lexaria Bioscience's change in net profit over the period of time. It can combine multiple indicators of Lexaria Bioscience, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-22.8 K-23.9 K
Operating Income-5.8 M-5.5 M
Income Before Tax-5.8 M-5.5 M
Total Other Income Expense Net-42.2 K-44.3 K
Net Loss-5.8 M-5.5 M
Income Tax Expense117.8 K123.7 K
Net Interest Income49.7 K52.2 K
Net Loss-6 M-6.3 M
Net Loss-6.5 M-6.9 M
Interest Income49.7 K52.2 K
Change To Netincome2.3 M1.3 M
Net Loss(0.47)(0.07)
Income Quality 0.85 (0.93)
Net Income Per E B T 1.00  1.16 

Lexaria Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lexaria Bioscience. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lexaria Bioscience position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lexaria Bioscience's important profitability drivers and their relationship over time.

Use Lexaria Bioscience in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexaria Bioscience position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexaria Bioscience will appreciate offsetting losses from the drop in the long position's value.

Lexaria Bioscience Pair Trading

Lexaria Bioscience Corp Pair Trading Analysis

The ability to find closely correlated positions to Lexaria Bioscience could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexaria Bioscience when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexaria Bioscience - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexaria Bioscience Corp to buy it.
The correlation of Lexaria Bioscience is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexaria Bioscience moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexaria Bioscience Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexaria Bioscience can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Lexaria Bioscience position

In addition to having Lexaria Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Obamacare Repeal Thematic Idea Now

Obamacare Repeal
Obamacare Repeal Theme
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Obamacare Repeal Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.